Kuros Biosciences appoints I.V. Hall as Chief Operating Officer, deepening operational, R&D and extremities leadership for next phase of growth
Schlieren (Zurich), Switzerland, May 7, 2026 – Kuros Biosciences (“Kuros” or the “Company”) a leader in next generation bone healing technologies, today announced the appointment of I.V. Hall as Chief Operating Officer effective June 1, 2026. I.V. will succeed Sjoerd Musters, who will conclude his role as the current Chief Operating Officer. By mutual agreement, Sjoerd will remain with the Company through August 1, 2026, to ensure a smooth transition of responsibilities.
This appointment reflects Kuros’ continued commitment to the organizational depth and operational infrastructure required to deliver on its innovative pipeline strategy. I.V. brings more than 30 years of medical device leadership experience with deep expertise in R&D, product development, commercialization, and strategic operations. He is widely recognized in the orthopedic trauma and extremities markets, making his appointment particularly relevant as Kuros continues to strengthen its presence across numerous musculoskeletal applications and accelerate the organic pipeline development.
I.V. joins Kuros following a distinguished career spanning orthopedic trauma, surgical infection prevention, and cardiology. He spent 27 years with DePuy Synthes, a Johnson & Johnson company (formerly Synthes), where he held positions of worldwide responsibility across R&D, commercialization, strategic marketing and business leadership, ultimately rising to Global President of the Trauma, Extremities, Craniomaxillofacial, and Animal Health businesses. He also served on the leadership team that facilitated the landmark integration of Synthes into Johnson & Johnson. Most recently, I.V. served as CEO and Managing Director of Next Science, LLC, where he led the commercialization of surgical solutions targeting infection prevention and successfully completed an asset sale to Demetra Holdings.
Chris Fair, Chief Executive Officer of Kuros Biosciences, said: “We sincerely thank Sjoerd for his pivotal role in building and strengthening Kuros’ operational foundation during this period of rapid growth. On behalf of the entire company, I appreciate his outstanding service and wish him continued success in his future endeavors.”
“As we enter our next stage of growth with a clear focus on translating scale into operational leverage, we are committed to building the organizational depth, infrastructure and product development capabilities required to deliver on our ambitious strategic plan. I.V. brings a rare combination of building and leading high-performing R&D-driven and operationally rigorous organizations, which is exactly what Kuros needs at this stage. His extensive experience in extremities, a key area of focus for us, combined with his proven ability to deliver complex product development programs, makes him an outstanding addition to our leadership team.”
Joost de Bruijn, Executive Director and President of Innovation and Strategy at Kuros Biosciences said: “I.V.’s experience sits directly at the intersection of innovation, product development and commercial execution. I am confident that his track record in leading global orthopedic businesses, advancing R&D programs and building high-performing organizations will help strengthen our innovation agenda and support the continued development of our pipeline.”
As incoming Chief Operating Officer, I.V. commented: “Kuros has built a strong innovation platform on a scientific foundation. I’ve spent my career building organizations that translate science into surgical solutions patients can count on. I am excited to join the team at the Company’s next wave of operational and innovative growth, especially as Kuros continues to build out its extremities portfolio and broader pipeline.”
I.V.’s appointment underscores Kuros’ continued focus on operational excellence, expanding organizational depth, technical expertise, and the organizational capabilities required to scale and advance its innovation strategy.